EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment

Nicola Principi iD, Valentina Fainardi iD, Susanna Esposito iD

Viruses · 20.08.2025 · 17 (8) · 1140

DOI: 10.3390/v17081140 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 20.08.2025. Verfasst von Nicola Principi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Università degli Studi di Milano, 20122 Milano, Italy. Hauptthemen laut MEDLINE: Metapneumovirus, Paramyxoviridae Infections, Respiratory Tract Infections. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGenerationEU-MUR, EU funding, One Health Basic and Translational Research Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human metapneumovirus (HMPV) is a major cause of acute respiratory tract infections, particularly in infants, young children, older adults, and immunocompromised individuals. Since its discovery in 2001, the virus has been recognized for its significant clinical and socioeconomic impact. Despite extensive research, no licensed vaccines or antiviral therapies are currently available for HMPV. This review aims to synthesize current knowledge on HMPV prevention and treatment, and to highlight promising avenues for future interventions. Several monoclonal antibodies (mAbs) targeting conserved epitopes of the HMPV fusion (F) protein have shown strong neutralizing activity in vitro and in animal models, although none have reached clinical trials. Vaccine development, including subunit, live attenuated, vector-based, and mRNA platforms, is progressing, with some candidates showing promise in adult populations. However, data in children, especially seronegative infants, remain limited. Antiviral research has explored repurposed drugs such as ribavirin and probenecid, along with novel agents like fusion inhibitors and T-cell-based immunotherapies, though none are yet approved. The development of safe, effective interventions—especially multivalent approaches targeting multiple respiratory viruses—remains a high priority. Continued research is essential to bridge the gap between preclinical promise and clinical application and to reduce the burden of HMPV infection worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetapneumovirusParamyxoviridae InfectionsRespiratory Tract InfectionsHumansAntiviral AgentsAnimalsViral VaccinesAntibodies, MonoclonalVaccine Development

Stichwörter der Autor:innen

antiviral therapyhuman metapneumovirusmonoclonal antibodiespediatric respiratory diseaserespiratory infectionsvaccine development

Substanzen

Antiviral AgentsViral VaccinesAntibodies, Monoclonal

Autor:innen und Institutionen

  • Università degli Studi di Milano, 20122 Milano, Italy.
  • Pediatric Clinic, Pietro Barilla Children's Hospital, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy.

ORCID-Profile: Nicola Principi, Valentina Fainardi, Susanna Esposito

Förderung

  • NextGenerationEU-MUR
  • EU funding
  • One Health Basic and Translational Research Actions

Zitieren

APA

Principi, N., Fainardi, V., & Esposito, S. (2025). Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment. Viruses, 17(8), 1140. https://doi.org/10.3390/v17081140

Vancouver

Principi N, Fainardi V, Esposito S. Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment. Viruses. 2025;17(8):1140. doi:10.3390/v17081140

BibTeX
@article{Principi2025,
  author = {Principi, Nicola and Fainardi, Valentina and Esposito, Susanna},
  title = {Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {8},
  pages = {1140},
  doi = {10.3390/v17081140}
}
Kostenlos starten →